261 related articles for article (PubMed ID: 37822882)
1. A disulfidptosis-related lncRNA prognostic model to predict survival and response to immunotherapy in lung adenocarcinoma.
Zhang HB; Pan JY; Zhu T
Front Pharmacol; 2023; 14():1254119. PubMed ID: 37822882
[No Abstract] [Full Text] [Related]
2. A disulfidptosis-related lncRNA signature for predicting prognosis and evaluating the tumor immune microenvironment of lung adenocarcinoma.
Song Z; Cao X; Wang X; Li Y; Zhang W; Wang Y; Chen L
Sci Rep; 2024 Feb; 14(1):4621. PubMed ID: 38409243
[TBL] [Abstract][Full Text] [Related]
3. Disulfidptosis-related lncRNAs signature predicting prognosis and immunotherapy effect in lung adenocarcinoma.
Hong S; Zhang Y; Wang D; Wang H; Zhang H; Jiang J; Chen L
Aging (Albany NY); 2024 Jun; 16():. PubMed ID: 38862217
[TBL] [Abstract][Full Text] [Related]
4. Development of a novel disulfidptosis-related lncRNA signature for prognostic and immune response prediction in clear cell renal cell carcinoma.
Wang N; Hu Y; Wang S; Xu Q; Jiao X; Wang Y; Yan L; Cao H; Shao F
Sci Rep; 2024 Jan; 14(1):624. PubMed ID: 38182642
[TBL] [Abstract][Full Text] [Related]
5. Disulfidptosis‑related lncRNA prognosis model to predict survival therapeutic response prediction in lung adenocarcinoma.
Sun X; Li J; Gao X; Huang Y; Pang Z; Lv L; Li H; Liu H; Zhu L
Oncol Lett; 2024 Aug; 28(2):342. PubMed ID: 38855504
[TBL] [Abstract][Full Text] [Related]
6. Multiomics Analysis of Disulfidptosis Patterns and Integrated Machine Learning to Predict Immunotherapy Response in Lung Adenocarcinoma.
Liu J; Li H; Zhang N; Dong Q; Liang Z
Curr Med Chem; 2024 Apr; ():. PubMed ID: 38685772
[TBL] [Abstract][Full Text] [Related]
7. Deciphering disulfidptosis: Uncovering a lncRNA-based signature for prognostic assessment, personalized immunotherapy, and therapeutic agent selection in lung adenocarcinoma patients.
Ma C; Zhao H; Sun Y; Ding W; Wang H; Li Y; Gu Z
Cell Signal; 2024 May; 117():111105. PubMed ID: 38369264
[TBL] [Abstract][Full Text] [Related]
8. Construction and Validation of a Reliable Disulfidptosis-Related LncRNAs Signature of the Subtype, Prognostic, and Immune Landscape in Colon Cancer.
Dong X; Liao P; Liu X; Yang Z; Wang Y; Zhong W; Wang B
Int J Mol Sci; 2023 Aug; 24(16):. PubMed ID: 37629096
[TBL] [Abstract][Full Text] [Related]
9. A cuproptosis-related lncRNA signature for predicting prognosis and immunotherapy response of lung adenocarcinoma.
Yu S; Tang L; Zhang Q; Li W; Yao S; Cai Y; Cheng H
Hereditas; 2023 Jul; 160(1):31. PubMed ID: 37482612
[TBL] [Abstract][Full Text] [Related]
10. Bioinformatics construction and experimental validation of a cuproptosis-related lncRNA prognostic model in lung adenocarcinoma for immunotherapy response prediction.
Li L; Cai Q; Wu Z; Li X; Zhou W; Lu L; Yi B; Chang R; Zhang H; Cheng Y; Zhang C; Zhang J
Sci Rep; 2023 Feb; 13(1):2455. PubMed ID: 36774446
[TBL] [Abstract][Full Text] [Related]
11. Cross-talk between necroptosis-related lncRNAs to construct a novel signature and predict the immune landscape of lung adenocarcinoma patients.
Wu J; Song D; Zhao G; Chen S; Ren H; Zhang B
Front Genet; 2022; 13():966896. PubMed ID: 36186456
[No Abstract] [Full Text] [Related]
12. Identification and validation of a disulfidptosis-related genes prognostic signature in lung adenocarcinoma.
Zhang Y; Sun J; Li M; Hou L; Wang Z; Dong H; Xu W; Jiang R; Geng Y; Guan C; Zhu Z; Wang H; Gong Q; Zhang G
Heliyon; 2024 Jan; 10(1):e23502. PubMed ID: 38223725
[TBL] [Abstract][Full Text] [Related]
13. Crosstalk among disulfidptosis-related lncRNAs in lung adenocarcinoma reveals a correlation with immune profile and clinical prognosis.
Liu S; Wang S; Guo J; Wang C; Zhang H; Lin D; Wang Y; Hu X
Noncoding RNA Res; 2024 Sep; 9(3):772-781. PubMed ID: 38590434
[TBL] [Abstract][Full Text] [Related]
14. A novel defined risk signature of cuproptosis-related long non-coding RNA for predicting prognosis, immune infiltration, and immunotherapy response in lung adenocarcinoma.
Ma C; Li F; Gu Z; Yang Y; Qi Y
Front Pharmacol; 2023; 14():1146840. PubMed ID: 37670938
[No Abstract] [Full Text] [Related]
15. Construction of a Prognostic Immune-Related LncRNA Risk Model for Lung Adenocarcinoma.
Li Y; Shen R; Wang A; Zhao J; Zhou J; Zhang W; Zhang R; Zhu J; Liu Z; Huang JA
Front Cell Dev Biol; 2021; 9():648806. PubMed ID: 33869203
[TBL] [Abstract][Full Text] [Related]
16. A novel senescence-related lncRNA signature that predicts prognosis and the tumor microenvironment in patients with lung adenocarcinoma.
Fang X; Huang E; Xie X; Yang K; Wang S; Huang X; Song M
Front Genet; 2022; 13():951311. PubMed ID: 36406130
[No Abstract] [Full Text] [Related]
17. Identification of disulfidptosis-related subgroups and prognostic signatures in lung adenocarcinoma using machine learning and experimental validation.
Wang Y; Xu Y; Liu C; Yuan C; Zhang Y
Front Immunol; 2023; 14():1233260. PubMed ID: 37799714
[TBL] [Abstract][Full Text] [Related]
18. Identification of a disulfidptosis-related genes signature for prognostic implication in lung adenocarcinoma.
Huang J; Zhang J; Zhang F; Lu S; Guo S; Shi R; Zhai Y; Gao Y; Tao X; Jin Z; You L; Wu J
Comput Biol Med; 2023 Oct; 165():107402. PubMed ID: 37657358
[TBL] [Abstract][Full Text] [Related]
19. Molecular typing and prognostic model of lung adenocarcinoma based on cuprotosis-related lncRNAs.
Zheng M; Zhou H; Xie J; Zhang H; Shen X; Zhu D
J Thorac Dis; 2022 Dec; 14(12):4828-4845. PubMed ID: 36647499
[TBL] [Abstract][Full Text] [Related]
20. Developing a prognostic model using machine learning for disulfidptosis related lncRNA in lung adenocarcinoma.
Pan Y; Jin X; Xu H; Hong J; Li F; Luo T; Zeng J
Sci Rep; 2024 Jun; 14(1):13113. PubMed ID: 38849442
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
